Ribociclib Extends Median Survival by Over 12 Months in Advanced Breast Cancer

First-line combination therapy achieves a median overall survival of 63.9 months, the longest reported in this setting, despite high crossover in the control arm.

Design MONALEESA-2 Phase 3 Trial Population Postmenopausal women with HR+, HER2- advanced breast cancer N 668 Duration Median follow-up 80 months Comparator Placebo + Letrozole Year 2022

Key Performance Indicators

PRIMARY

Hazard Ratio (Death)

0.76

95% CI: 0.63–0.93

24% reduction in risk of death

PRIMARY

Median OS Benefit

+12.5 mo

63.9 vs 51.4 months

Clinically meaningful extension

P-Value

0.008

Two-sided

Statistically significant

6-Year Survival Rate

44.2%

vs 32.0% in Placebo

Long-term benefit

01

Median Overall Survival exceeds 5 years with Ribociclib

Patients receiving Ribociclib lived a median of 12.5 months longer than those on Placebo, breaking the 5-year barrier in this setting.

02

Survival benefit widens significantly over time

The absolute difference in survival rates increases from 5.7% at 4 years to 12.2% at 6 years, indicating sustained long-term efficacy.

03

Survival advantage is consistent across key subgroups

Hazard ratios favor Ribociclib across age groups and metastatic sites. The benefit is particularly pronounced in patients ≥65 years.

04

Ribociclib delays the need for subsequent chemotherapy

Treatment delayed the time to first subsequent chemotherapy by nearly one year compared to placebo.

05

OS benefit persists despite higher post-progression CDK4/6 use in placebo arm

More patients in the placebo group received CDK4/6 inhibitors as subsequent therapy, yet the Ribociclib arm still maintained a significant survival advantage.

06

Safety Profile: Neutropenia is the primary trade-off

Grade 3 or 4 adverse events were dominated by neutropenia in the Ribociclib arm, while other severe toxicities remained relatively low.

Editorial Conclusion

“Ribociclib plus letrozole demonstrates a statistically significant and clinically substantial overall survival benefit of over 1 year compared to placebo.”

Median OS of 63.9 months is the longest reported in this patient population.

Benefit is consistent across subgroups and persists despite 34.4% of placebo patients receiving subsequent CDK4/6 inhibitors.

Chemotherapy initiation was delayed by approximately 12 months.

Clinical Implication

These findings support the use of Ribociclib plus Letrozole as the standard first-line treatment for postmenopausal women with HR+, HER2- advanced breast cancer.

Reference Data Sources & Abbreviations

Abbreviations

Abbrev	Meaning
OS	Overall Survival
HR	Hazard Ratio
CI	Confidence Interval
CDK4/6	Cyclin-dependent kinases 4 and 6

Source

N Engl J Med 2022;386:942-50.

DOI: 10.1056/NEJMoa2114663

Limitations

Black patients were underrepresented (2.5%).
High crossover to CDK4/6 inhibitors in placebo arm required statistical adjustment (RPSFT model) to confirm benefit magnitude.